Bendroflumethiazide

País: Nova Zelândia

Língua: inglês

Origem: Medsafe (Medicines Safety Authority)

Ingredientes ativos:

Bendroflumethiazide 2.5mg;  ;  

Disponível em:

Ipca Pharma (NZ) Pty Limited

DCI (Denominação Comum Internacional):

Bendroflumethiazide 2.5 mg

Dosagem:

2.5 mg

Forma farmacêutica:

Tablet

Composição:

Active: Bendroflumethiazide 2.5mg     Excipient: Lactose Purified talc Starch Stearic acid

Unidades em pacote:

Blister pack, PVC/PVDC, 14 tablets

Classe:

Prescription

Tipo de prescrição:

Prescription

Fabricado por:

Ipca Laboratories Limited

Indicações terapêuticas:

Bendrofluazide is indicated in the treatment of oedema associated with conditions such as: congestive heart failure, nephrotic syndrome and cirrhosis of the liver.

Resumo do produto:

Package - Contents - Shelf Life: Blister pack, PVC/PVDC - 14 tablets - 24 months from date of manufacture stored at or below 25°C - Blister pack, PVC/PVDC - 28 tablets - 24 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE - 500 tablets - 24 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE - 1000 tablets - 24 months from date of manufacture stored at or below 25°C

Data de autorização:

2006-06-28